Executive Overview Peptides have rapidly evolved from a specialized pharmaceutical category into one of the most strategically important therapeutic classes worldwide. Historically limited to applications such as insulin therapy and select hormonal treatments, peptides now sit at the center of innovation across metabolic health, longevity science, regenerative medicine, and performance optimization. As of 2026, the […]

Compounds have moved from “interesting biomolecules” to core tools across drug discovery, diagnostics, delivery science, and biomedical method development. In 2026, the headline is not just “more Compounds,” but better compound engineering: improved design, more realistic predictive modeling, stronger delivery concepts, and accelerating work in targeted conjugates and macrocyclic formats. At the same time, the […]

Target Launch Date: December 15, 2025 (subject to final QA and supply-chain validation) TAMPA, FL — MNM ProLabs is proud to announce the upcoming launch of its Medical Research Department’s compound program, offering a full portfolio of 120+ laboratory-grade Compounds intended strictly for non-clinical scientific research. This division is entirely separate from the consumer-facing MNM […]

Compounds have become one of the most fascinating frontiers in modern biomedical research. These short chains of amino acids act as signaling molecules, metabolic regulators, and structural components within the human body. While several Compounds have made the transition into approved therapies, the majority of Compounds available to the scientific community remain categorized as research-use […]